|
1
|
Li S, Zhang C, Pang G and Wang P: Emerging
blood-based biomarkers for predicting response to checkpoint
immunotherapy in non-small-cell lung cancer. Front Immunol.
11(603157)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–1355.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Möller M, Turzer S, Schütte W, Seliger B
and Riemann D: Blood immune cell biomarkers in patient with lung
cancer undergoing treatment with checkpoint blockade. J Immunother.
43:57–66. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Davis AA and Patel VG: The role of PD-L1
expression as a predictive biomarker: An analysis of all US food
and drug administration (FDA) approvals of immune checkpoint
inhibi. J Immunother Cancer. 7(278)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Marcus L, Lemery SJ, Keegan P and Pazdur
R: FDA approval summary: Pembrolizumab for the treatment of
microsatellite instability-high solid tumors. Clin Cancer Res.
25:3753–3758. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Prasad V and Addeo A: The FDA approval of
pembrolizumab for patients with TMB >10 mut/Mb: Was it a wise
decision? No. Ann Oncol. 31:1112–1114. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bai R, Lv Z, Xu D and Cui J: Predictive
biomarkers for cancer immunotherapy with immune checkpoint
inhibitors. Biomark Res. 8(34)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim
TM, Kim DW, Heo DS and Lee JS: Post-treatment
neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients
with advanced non-small cell lung cancers treated with anti-PD-1
antibody. Cancer Immunol Immunother. 67:459–470. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Keegan A, Ricciuti B, Garden P, Cohen L,
Nishihara R, Adeni A, Paweletz C, Supplee J, Jänne PA, Severgnini
M, et al: Plasma IL-6 changes correlate to PD-1 inhibitor responses
in NSCLC. J Immunother Cancer. 8(e000678)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sun JY and Lu XJ: Cancer immunotherapy:
Current applications and challenges. Cancer Lett. 480:1–3.
2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hussaini S, Chehade R, Boldt RG, Raphael
J, Blanchette P, Maleki Vareki S and Fernandes R: Association
between immune-related side effects and efficacy and benefit of
immune checkpoint inhibitors-a systematic review and meta-analysis.
Cancer Treat Rev. 92(102134)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Music M, Iafolla M, Soosaipillai A,
Batruch I, Prassas I, Pintilie M, Hansen AR, Bedard PL, Lheureux S,
Spreafico A, et al: Predicting response and toxicity to PD-1
inhibition using serum autoantibodies identified from immuno-mass
spectrometry. F1000Res. 9(337)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Scally SW, Petersen J, Law SC, Dudek NL,
Nel HJ, Loh KL, Wijeyewickrema LC, Eckle SB, van Heemst J, Pike RN,
et al: A molecular basis for the association of the HLA-DRB1 locus,
citrullination, and rheumatoid arthritis. J Exp Med. 210:2569–2582.
2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kapustin S, Lyshchov A, Alexandrova J,
Imyanitov E and Blinov M: HLA class II molecular polymorphisms in
healthy Slavic individuals from North-Western Russia. Tissue
Antigens. 54:517–520. 1999.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lalani AA, Xie W, Martini DJ, Steinharter
JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van
Allen EM, et al: Change in neutrophil-to-lymphocyte ratio (NLR) in
response to immune checkpoint blockade for metastatic renal cell
carcinoma. J Immunother Cancer. 6(5)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang
G, Chen R, Jiao S and Wang J: Pretreatment neutrophil-to-lymphocyte
ratio (NLR) may predict the outcomes of advanced non-small-cell
lung cancer (NSCLC) patients treated with immune checkpoint
inhibitors (ICIs). Front Oncol. 10(654)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jin J, Yang L, Liu D and Li W: Association
of the neutrophil to lymphocyte ratio and clinical outcomes in
patients with lung cancer receiving immunotherapy: A meta-analysis.
BMJ Open. 10(e035031)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Li L, Dong M and Wang XG: The implication
and significance of beta 2 microglobulin: A conservative
multifunctional regulator. Chin Med J (Engl). 129:448–455.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rossi D, Fangazio M, De Paoli L, Puma A,
Riccomagno P, Pinto V, Zigrossi P, Ramponi A, Monga G and Gaidano
G: Beta-2-microglobulin is an independent predictor of progression
in asymptomatic multiple myeloma. Cancer. 116:2188–2200.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xie J, Wang Y, Freeman ME III, Barlogie B
and Yi Q: Beta 2-microglobulin as a negative regulator of the
immune system: High concentrations of the protein inhibit in vitro
generation of functional dendritic cells. Blood. 101:4005–4012.
2003.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Volgger BM, Windbichler GH, Zeimet AG,
Graf AH, Bogner G, Angleitner-Boubenizek L, Rohde M, Denison U,
Sliutz G, Fuith LC, et al: Long-term significance of urinary
neopterin in ovarian cancer: A study by the Austrian association
for gynecologic oncology (AGO). Ann Oncol. 27:1740–1746.
2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Melichar B, Spisarová M, Bartoušková M,
Krčmová LK, Javorská L and Študentová H: Neopterin as a biomarker
of immune response in cancer patients. Ann Transl Med.
5(280)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang
S, Yang Y, Zhang S, Feng X, Sun N and Wang Y: Systematic analysis
of IL-6 as a predictive biomarker and desensitizer of immunotherapy
responses in patients with non-small cell lung cancer. BMC Med.
20(187)2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Laino AS, Woods D, Vassallo M, Qian X,
Tang H, Wind-Rotolo M and Weber J: Serum interleukin-6 and
C-reactive protein are associated with survival in melanoma
patients receiving immune checkpoint inhibition. J Immunother
Cancer. 8(e000842)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Fabbi M, Carbotti G and Ferrini S:
Context-dependent role of IL-18 in cancer biology and
counter-regulation by IL-18BP. J Leukoc Biol. 97:665–675.
2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang Y, Chen H, Zhang T, Yang X, Zhong J,
Wang Y, Chi Y, Wu M, An T, Li J, et al: Plasma cytokines
interleukin-18 and C-X-C motif chemokine ligand 10 are indicative
of the anti-programmed cell death protein-1 treatment response in
lung cancer patients. Ann Transl Med. 9(33)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Terme M, Ullrich E, Aymeric L, Meinhardt
K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G,
et al: IL-18 induces PD-1-dependent immunosuppression in cancer.
Cancer Res. 71:5393–5399. 2011.PubMed/NCBI View Article : Google Scholar
|
